Galapagos has dosed the first patient in the Phase II PINTA trial designed to evaluate GLPG1205 for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

The patient was dosed in a trial centre in Slovakia.

Galapagos chief scientific officer Dr Piet Wigerinck said: “The first patient dosing in our PINTA Phase II trial shows the progress we are making in expanding our IPF franchise.

“We are strongly committed to the rapid development of our fully proprietary IPF portfolio to address this important unmet medical need.”

The randomised, double-blind, placebo-controlled trial aims to include up to 60 IPF patients across ten countries in Europe, North Africa, and the Middle East.

“The first patient dosing in our PINTA Phase II trial shows the progress we are making in expanding our IPF franchise.”

During the trial, patients will receive a 100mg once-daily oral dose of GLPG1205 or placebo for 26 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients will have the option to remain on their local standard of care as background therapy, irrespective of whether they were previously or are currently being treated with esbriet (pirfenidone) and ofev (nintedanib).

The trial’s primary goal is to evaluate the change from baseline in Forced Vital Capacity (FVC in mL) over 26 weeks compared to placebo.

Its secondary goals comprise safety, tolerability, pharmacokinetics and pharmacodynamics, time to major events, changes in functional exercise capacity, and quality of life.

Galapagos’s GLPG1205 is a small molecule selectively antagonising GPR84, which plays a role in IPF.

IPF is a chronic, persistently developing fibrotic disorder of lungs that usually affects adults over the age of 40.